Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Taysha Gene Therapies Inc (TSHA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $135000.00 | $-30.73M | $-117.04M | $-88.39M | $-73.02M | $-81.22M | $-93.09M |
| Capital expenditures | $82000.00 | $9.08M | $21.55M | $24.87M | $7.37M | $374000.00 | $738000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $3.35M | $18.18M | $18.04M | $7.91M | $13.10M | $13.30M |
| Free cash flow | $53000.00 | $-39.81M | $-138.60M | $-113.26M | $-80.39M | $-81.60M | $-93.83M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | $251.25M | — | — | — | — | — |
Frequently asked questions
What is Taysha Gene Therapies Inc's revenue?
Taysha Gene Therapies Inc's trailing twelve-month revenue is $7.47M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is TSHA?
In its most recent fiscal year, TSHA ran a gross margin of 100.00%, an operating margin of -1,130.65%, and a net margin of -1,115.27%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does TSHA generate?
TSHA produced $-93.83M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is TSHA's balance sheet healthy?
TSHA holds $319.77M in cash and equivalents against $50.11M in long-term debt, on $246.94M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.